Nippon
Navigation Links
Nippon in Medical News
GlycoMark(R) Blood Test Now Established to Provide Physicians with Vital Information Missed by Hemoglobin A1c Test to More Effectively Manage Patients with Diabetes
NEW YORK and WINSTON-SALEM, N.C., July 17 /PRNewswire/ -- Toyota Tsusho
America, Inc. (New York, NY) and...
...an, have signed the Appeal. Mr Sasakawa, who is also Chairman of the nippon Foundation, pointed out that "since an effective cure became available in t...o their believers and followers." Contact: Keiko Mori The nippon Foundation Tel: +81-3-6229-5131 e-mail: k_mori@ps.nippon-foundatio...
... Their Care NEW YORK, Jan. 12 /PRNewswire/ -- nippon Life Benefits, a leading provider of employee bene...able to existing and new employer group clients of nippon Life Benefits. "Best Doctors offers our plan ...a Hosoda, president and chief executive officer of nippon Life Benefits. "Helping members make informed dec...
Small-Cell Lung Cancer Drug Market Will More Than Double to Over $684 Million in 2017
...than $684 million in 2017, owing to the launches of Genentech/Roche/Chugai's Avastin and Celgene's amrubicin (currently marketed in Japan as Calsed by nippon Kayaku) to treat the indication. The new Pharmacor report entitled Small-Cell Lung Cancer finds that the launches, beginning in 2012, of Avast...Bausch & Lomb Japan Names Mitsuo Hirose as Chairman
...recently he was representative director and chairman of Pacific Golf Group International Holdings KK. Prior roles included serving as president of Dai nippon Printing Company's U.S. operations, and as a founder of corporate governance and ethics consultancy Maverick Japan Inc. In addition, Mr. Hirose ......an, have signed the Appeal. Mr Sasakawa, who is also Chairman of the nippon Foundation, pointed out that "since an effective cure became available in t...o their believers and followers." Contact: Keiko Mori The nippon Foundation Tel: +81-3-6229-5131 e-mail: k_mori@ps.nippon-foundatio...
... Their Care NEW YORK, Jan. 12 /PRNewswire/ -- nippon Life Benefits, a leading provider of employee bene...able to existing and new employer group clients of nippon Life Benefits. "Best Doctors offers our plan ...a Hosoda, president and chief executive officer of nippon Life Benefits. "Helping members make informed dec...
Study reports Double Balloon Endoscopy useful for diagnosis and treatment of obscure GI bleeding
...ll GI bleeding remains undiagnosed," said study lead author Shu Tanaka, MD, nippon Medical School, Tokyo, Japan. "Until now, there has been no in-depth analys...scopy." Patients and Methods This study examined 108 patients at the nippon Medical School, Tokyo, Japan from July 2003 to February 2007 who had been r...P&G Recognizes Top Performing Suppliers
...ticularly to P&G's blades, razors and Duracell businesses; -- Jones Lang LaSalle of Chicago, Illinois providing facilities management services; -- nippon Shokubai of Tokyo, Japan providing absorbent gel material for P&G's diaper business; -- Novozymes of Bagsvaerd, Denmark is an enzyme supplier for P&...Zimmer Holdings Names Mark C. Throdahl Group President, Global Businesses
...corporate headquarters where he served as Senior Vice President and President of Drug Delivery, and in Japan, where he held the position of President, nippon Becton Dickinson. He started his medical devices career in 1975 with Mallinckrodt Group, where he held sales and marketing positions of increasing res...Martek Signs Exclusive Worldwide Distributorship Agreement with Novus International
...onal, Inc., focuses on developing performance products for the equine, canine, and human markets. Novus is privately owned by Mitsui and Co., Ltd. and nippon Soda Co., Ltd. For more information visit http://www.novusint.com . Martek Biosciences Corporation (Nasdaq: MATK ) is a leader in the innovation an...GlycoMark Blood Test Included in Global Diabetes Care Guidelines as Emerging Technology
...e rises is a key objective of diabetes drug therapy. GlycoMark is being commercialized by a partnership between Toyota Tsusho America (New York, NY), nippon Kayaku (Tokyo, Japan) and the BioMarker Group (Kannapolis, NC). GlycoMark activities are centered in the North Carolina Research Campus in Kannapolis,...Nippon in Medical Technology
...osclerosis. It was selected for
clinical development from a series of small molecule compounds available to
Cerenis through a licensing agreement with nippon Chemiphar Co., Ltd.
"CER-002 is a novel compound which has shown significant
antiatherosclerotic properties in animal models even at low doses. The
...
...ts, royalties and/or profits from sales of the product in Japan. Japanese rights for all potential oncology indications have recently been licensed to nippon Kayaku, a key player in the Japanese oncology market. Spectrum is developing ozarelix for benign prostatic hypertrophy (BPH), hormone-dependent pros...
...profits from sales of the product in Japan. Furthermore, AEterna Zentaris recently granted Japanese rights for all potential oncology indications to nippon Kayaku, a key player in the Japanese oncology market. About Benign Prostatic Hyperplasia Benign prostatic hyperplasia (BPH) is a non-cancerous enl...
... was approved and launched for sale in Japan based on Phase 2 efficacy data in both SCLC and NSCLC. Since January 2005, Amrubicin has been marketed by nippon Kayaku, a Japanese pharmaceutical firm focused on oncology, which licensed Japanese marketing rights from Dainippon Sumitomo, the original developer o...
Pharmion Initiates Pivotal Phase 3 Study of Amrubicin in Small Cell Lung Cancer
... was approved and launched for sale in Japan based on Phase 2 efficacy data in both SCLC and NSCLC. Since January 2005, amrubicin has been marketed by nippon Kayaku, a Japanese pharmaceutical firm focused on oncology, which licensed Japanese marketing rights from Dainippon Sumitomo, the original developer o...Ozarelix Phase 2 Data Presented at 29th Congress of the Societe Internationale d'Urologie
...ts, royalties and/or profits from sales of the product in Japan. Japanese rights for all potential oncology indications have recently been licensed to nippon Kayaku, a key player in the Japanese oncology market. Spectrum is developing ozarelix for benign prostatic hypertrophy (BPH), hormone-dependent prost......ts, royalties and/or profits from sales of the product in Japan. Japanese rights for all potential oncology indications have recently been licensed to nippon Kayaku, a key player in the Japanese oncology market. Spectrum is developing ozarelix for benign prostatic hypertrophy (BPH), hormone-dependent pros...
...profits from sales of the product in Japan. Furthermore, AEterna Zentaris recently granted Japanese rights for all potential oncology indications to nippon Kayaku, a key player in the Japanese oncology market. About Benign Prostatic Hyperplasia Benign prostatic hyperplasia (BPH) is a non-cancerous enl...
... was approved and launched for sale in Japan based on Phase 2 efficacy data in both SCLC and NSCLC. Since January 2005, Amrubicin has been marketed by nippon Kayaku, a Japanese pharmaceutical firm focused on oncology, which licensed Japanese marketing rights from Dainippon Sumitomo, the original developer o...
Nippon in Medical Products
Growth Hormone Binding Protein ELISA Test
Description:...276, 2002. Hansen TK et al. J Clin Endocrinol Metab 87 (10): 4691-4698, 2002. Baumann G J Pediatr Endocrinol Metab 15 (7): 959-961, 2002. Kaji H nippon Rinsho 60 (2): 306-312, 2002....Company:Diagnostic Systems Laboratories, Inc.
Nippon in Biological News
Springer and the Physiological Society of Japan sign publishing agreement
...mphasis is on human and vertebrate physiology, comparative papers are also included. Dr. Yasuo Sakuma, head of the Department of Physiology at the nippon Medical School in Tokyo and Editor-in-Chief of The Journal of Physiological Sciences , said, "In the post-genome era, increasing interest is being de...Nippon in Biological Technology
...siness plan to launch 8-10 new
products each year, nippon Universal Pharmaceutical Co. Ltd., a subsidiary of...
Japan generic market. In 2007, the group acquired nippon Universal, a small
generic company which now spear...n Japan.
With a focus on quality medicines, nippon Universal will be leveraging
Zydus' capabilities i...
...urope in 1999 and in the United States in 2001. Cetrotide(R) is currently marketed worldwide by Merck Serono, except for Japan where it is marketed by nippon Kayaku and Shionogi. Cetrorelix is also currently in a Phase 3 program in benign prostatic hyperplasia involving 1,500 patients in North America a...
...urope in 1999 and in the United States in 2001. Cetrotide(R) is currently marketed worldwide by Merck Serono, except for Japan where it is marketed by nippon Kayaku and Shionogi. Cetrorelix is also currently in a Phase 3 program in benign prostatic hyperplasia involving 1,500 patients in North America and...
New Report Just Published: World Prostate Cancer Therapeutics Market Report
... 'Prostate-63' Tests II-79 Mylan Pharmaceuticals Obtains FDA Approval for Finasteride's ANDA II-79 Aeterna Zentaris Enters into Agreement with nippon Kayaku II-79 Progenics Pharmaceuticals Broadens Association with Seattle Genetics II-80 Diosynth and Dendreon Sign Multi-Year Commercial S......urope in 1999 and in the United States in 2001. Cetrotide(R) is currently marketed worldwide by Merck Serono, except for Japan where it is marketed by nippon Kayaku and Shionogi. Cetrorelix is also currently in a Phase 3 program in benign prostatic hyperplasia involving 1,500 patients in North America a...
...urope in 1999 and in the United States in 2001. Cetrotide(R) is currently marketed worldwide by Merck Serono, except for Japan where it is marketed by nippon Kayaku and Shionogi. Cetrorelix is also currently in a Phase 3 program in benign prostatic hyperplasia involving 1,500 patients in North America and...
Lixte Biotechnology Holdings Announces New Appointment to Board of Directors
... Bayer, he was very active in business development, facilitating several in-licensing agreements and joint collaborations (including Onyx, SB, Corixa, nippon Kayaku, and Hoffmann-La Roche). Dr. Sorensen joined Ascenta Therapeutics in August 2004. Under his leadership, in less than three years Ascenta was ...Replidyne Announces Second Quarter 2008 Results From Operations
...inated its supply agreement with Asubio Pharma and nippon Soda Co., Ltd. (Nippon Soda) for production of far...mbursement of engineering costs of $0.6 million to nippon Soda in accordance with the terms of the agreements. Replidyne also paid nippon Soda $0.9 million for delay compensation under the...Replidyne Terminates Faropenem Agreements
...s supply agreement of up to Japanese Yen 65 (approximately $0.6 million) to nippon Soda Co. Ltd. Replidyne will also pay nippon Soda Co. Ltd. Japanese Yen 99 million (approximately $0.9 million) for dela...AEterna Zentaris' Partner, Spectrum, Provides Update on Ozarelix in Benign Prostatic Hyperplasia
...s from sales of ozarelix in Japan. On July 26, 2006 AEterna Zentaris licensed the Japanese rights for all ozarelix potential oncology indications to nippon Kayaku, a key player in the Japanese oncology market. About Cetrorelix Cetrorelix pamoate is an investigational agent that has demonstrated in Pha...Schering-Plough Announces Sugammadex New Drug Application Filed in Japan
... KENILWORTH, N.J., Jan. 17 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP ) announced that nippon Organon K.K., now part of Schering-Plough, has filed a New Drug Application with the Japanese Ministry of Health, Labour and Welfare (MHLW) seeking ma...Martek Announces Fourth Quarter and FY 2007 Financial Results
...distributorship agreement for Martek's DHA Gold(R) animal feed product with Novus International, Inc, an affiliate of Mitsui and Co., Ltd. and nippon Soda Co., Ltd. Martek will serve as Novus's sole source supplier of DHA for all of its poultry and swine feed and enrichment products. All No...Other TagsEclampsiaEdemaOther Contentsgynecologygynecologygynecologygynecologygynecomastiahairyhallucinationshallucinationshallucinationsvalgusvalgushalluxhammertoetoetoetoe
DyspepsiaDyshidroticDysphoniaDysplasiaDysthymiaEaracheEcchymosisEarwaxEchocardiogramEctropionEclampsiaEctodermalEdemaElectrocauterization
(Date:12/16/2009)... -- Smart Balance, Inc. (Nasdaq: SMBL ) announced ... two-year stock repurchase program of up to $25 million, ... the confidence we have in the prospects of our ... for all of our shareholders, while at the same ... Smart Balance, Inc. Chairman and Chief Executive Officer. ,, ...
(Date:12/16/2009)... minorities might not gain full benefit from breakthroughs, experts ... embryonic stem cell lines currently used for research come ... , That could mean that non-whites will benefit less ... down the line, experts say. , Blacks could be ... used stem cell lines studied showed any traces of ...
(Date:12/16/2009)... Dec. 16 For wounded U.S. ... Center in Washington, D.C., the holidays can be a ... to travel home rely more than ever on the ... This week, calling home just got easier for Walter ... calling cards, which will provide hundreds of minutes of ...
(Date:12/16/2009)... deadly, attack is long-term goal, researchers say , , ... a tool to predict whether a patient will suffer ... stroke. , "This is an important new tool because ... stroke soon after a first stroke are more likely ... of Massachusetts General Hospital and Harvard Medical School, said ...
(Date:12/16/2009)... an advance that could help ease health and environmental ... development of technology for changing the behavior of nanoparticles ... into the environment. Their study was published in ACS, ... Jarvie from the UK Centre for Ecology and Hydrology ... the production of nanoparticles particles less than 1/1000th ...
Breaking Medicine News(10 mins):Health News:Smart Balance Authorizes Stock Repurchase Program 2Health News:Most Stem Cells Used in Research Come From Whites 2Health News:Verizon Wireless Donates $10,000 in Long-Distance Calling Cards to Soldiers at Walter Reed Hospital 2Health News:New Stroke Tool May Predict Early Recurrence 2Health News:Behavior modification could ease concerns about nanoparticles 2[0] Smart Balance Authorizes Stock Repurchase Program[0] Most Stem Cells Used in Research Come From Whites[0] Verizon Wireless Donates $10,000 in Long-Distance Calling Cards to Soldiers at Walter Reed Hospital[0] New Stroke Tool May Predict Early Recurrence[0] Behavior modification could ease concerns about nanoparticles
(Date:12/16/2009)... European Union (EU) member states ... which are increasingly subjected to unauthorised immigration ... advanced technology security and IT-based systems will ... http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO ) ,, New analysis from ... Border Security Market Assessment - European Union ...
(Date:12/15/2009)... soon as babies are born, they are susceptible to ... up to a month, their immune systems aren,t adequately ... minor, they can lead to serious problems if left ... Missouri researchers have pinpointed a group of depleted white ... , "We,re trying to improve the immune system of ...
(Date:12/15/2009)... signed an agreement with the British Society for Research ... the journal Biogerontology for an initial period ... member of the Biogerontology editorial board and ... Springer will sponsor the society and provide society members ... www.springerlink.com . , Biogerontology offers a ...
Breaking Biology News(10 mins):Increased Spending on the EU's External Borders to Drive the Border Security Market, Says Frost & Sullivan 2Increased Spending on the EU's External Borders to Drive the Border Security Market, Says Frost & Sullivan 3Researchers work on vaccine to improve immune system in newborns 2Elbit Imaging Ltd Announces Swiss Team Uses InSightecs ExAblate 28R 29 4000 Brain System to Treat Patients With Functional Brain Disorders 4721 1Elbit Imaging Ltd Announces Swiss Team Uses InSightecs ExAblate 28R 29 4000 Brain System to Treat Patients With Functional Brain Disorders 4721 2Elbit Imaging Ltd Announces Swiss Team Uses InSightecs ExAblate 28R 29 4000 Brain System to Treat Patients With Functional Brain Disorders 4721 3Elbit Imaging Ltd Announces Swiss Team Uses InSightecs ExAblate 28R 29 4000 Brain System to Treat Patients With Functional Brain Disorders 4721 4Simulating medical situations helps students learn retain basic science concepts 51568 1Simulating medical situations helps students learn retain basic science concepts 51568 2July August 2009 Annals of Family Medicine tip sheet 51565 1July August 2009 Annals of Family Medicine tip sheet 51565 2July August 2009 Annals of Family Medicine tip sheet 51565 3July August 2009 Annals of Family Medicine tip sheet 51565 4July August 2009 Annals of Family Medicine tip sheet 51565 5July August 2009 Annals of Family Medicine tip sheet 51565 6July August 2009 Annals of Family Medicine tip sheet 51565 7| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |